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1. Introduction 
Chronic pancreatitis (CP) has been defined as a continuing inflammatory disease of the 
pancreas characterized by irreversible morphological changes, often associated with pain 
and with the loss of exocrine and endocrine function which may be clinically relevant (Clain 
JE Surg Clin North Am 1999). Pain is the principal cause of intractability and together with 
pancreatic insufficiency may have a significantly deleterious effect on a patient’s quality of 
life as well as their ability to work and contribute to society, often leading to loss of their’ 
social support network (Lankisch PG Digestion 1993). Progressive disease may culminate in 
severe and disabling symptoms requiring narcotic analgesia and frequent hospital 
admission with a consequent impact on health resources (Bornman PC W J Surg 2003; 
Braganza JM The Lancet 2011). The incidence and prevalence of disease has not been well 
documented however it is considered uncommon in Europe and the USA. This is in contrast 
to data available from South India where a prevalence of 114-200/100 000 people has been 
documented. Alcohol is the leading cause in western developed countries and some 
developing countries such as Brazil, Mexico and South Africa while idiopathic disease 
predominates in Asia and the subcontinent (Braganza JM The Lancet 2011; Garg PK J 
Gastroenterol Hepatol 2004).  
Despite extensive study, the pathogenesis of chronic pancreatitis and the mechanisms 
which result in the development of pain remain poorly understood. As a result, treatment 
strategies have been largely empirical and based on symptoms, management of clinically 
evident exocrine and endocrine dysfunction and gross morphological abnormalities. 
Modalities employed have included medical support (with analgesics, anti-diabetic 
medication, pancreatic enzyme replacement, nutrient support and steroids in 
autoimmune disease), interventional endoscopy and surgery. The role of surgery has been 
primarily to relieve pain refractory to medical therapy, to address complications and to 
resect suspected or confirmed neoplastic disease (Bornman PC S Afr Med J 2010). The 
causes of pain in CP are likely multifactorial and proposed factors include excessive 
oxygen-derived free radicals, tissue hypoxia and acidosis, inflammatory infiltration 
accompanied by an influx of pain transmitted substances into damaged nerve ends and 
the development of pancreatic ductal and tissue fluid hypertension (Bornman PC W J 
Surg 2003). Surgical intervention for the relief of pain focuses primarily on the latter two 
proposed mechanisms. Two distinct principles have been applied in the development of 
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procedures to address these mechanisms. Resection of diseased pancreatic tissue, in 
particular inflamed tissue within the head of the pancreas containing altered neural tissue 
and diseased ducts, considered the “pacemaker of disease” (Beger HG World J Surg 1990) 
and drainage of the pancreatic ductal system, in order to relieve ductal and parenchymal 
tissue hypertension. Removal of sufficient pancreatic tissue as to result in effective and 
durable relief of symptoms must however be balanced against the desire to avoid 
surgically related morbidity and mortality as well as to prevent post-operative pancreatic 
functional insufficiency. This has led to the development of less extensive resections and 
hybrid procedures which attempt to combine the advantages while avoiding the 
disadvantages of each approach. 
This chapter will describe the theories around the pathophysiology of pain in chronic 
pancreatitis, discuss the rationale and indications for surgical intervention and detail the 
procedures currently available. It will also review the literature guiding the choice of these 
procedures for the relief of pain.  
2. Pathophysiology of pain in chronic pancreatitis 
The pathophysiology of CP is complex and remains poorly understood, with a number of 
theories having been put forward. Together with this, understanding of the mechanisms 
leading to the development of pain has also remained largely theoretical, confounded to a 
large extent by small and to some degree poorly designed studies, which have at times been 
contradictory. Furthermore, it is likely that the cause of pain is multi-factorial and may vary 
during the course of the disease (Bornman PC W J Surg 2003). To date, the most 
predominant theories regarding genesis of pain in CP have included: 
2.1 Morphological pancreatic ductal changes resulting in obstruction and pancreatic 
ductal and tissue hypertension 
In large duct chronic pancreatitis, changes in the composition of pancreatic fluid occur 
including an increase in free oxygen radicals and secretion of enzymes and calcium but a 
concomitant decrease in serine protease inhibitor Kazal type 1 (SPINK1), bicarbonate and 
citrate. (Sarles H Dig Dis Sci 1986). These changes are followed by precipitation of proteins 
such as lactoferrin and altered levels of pancreas related secretory stress proteins (including 
pancreatitis associated protein and pancreatic stone protein) (Singh SM W J Surg 1990; Graf 
R J Surg Res 2006). Glycoprotein plugs are formed which later become calcified leading to 
calcific disease with associated parenchymal fibrosis. Calcified protein plugs or calculi 
damage the ductal epithelium further and contribute to stasis thereby facilitating further 
stone formation. These changes are believed to begin in the side ducts but progress to 
involve the main pancreatic duct (PD) with the development of pancreatic duct strictures 
and obstruction (PDSO) as a consequence of fibrosis or calculi. Ductal hypertension follows 
with associated dilatation (Nagata A Gatroenteology 1981). Together with ductal 
hypertension, pancreatic tissue pressure may become elevated, particularly in areas of 
calcification (Okazaki K Gastroenterology 1986; Manes G Int J Pancreatol 1994; Jalleh RPBr J 
Surg 1991). The exact mechanism of elevated PTP in CP has not been proven, however it has 
been speculated that it may be a reflection of obstructed pancreatic side ducts rather than 
main PD obstruction. This situation may be aggravated by the development of perilobular 
fibrosis and a fibrotic peripancreatic capsule, resulting in a compartment syndrome like 
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scenario with consequent tissue ischaemia and acidosis. (Karanjia ND Br J Surg 1994). While 
PDSO with ductal and tissue hypertension have not been consistently demonstrated in CP, 
nor a definite correlation shown with the development of pain (Novis BH Dig Dis Sc 1985; 
Manes G Int J Pancreatol 1994; Ugljesic M Int J Pancreatol. 1996; Bornman PC W J Surg 
2003), surgical drainage procedures have been documented to reduce pancreatic tissue 
pressures (PTP), while a significant association between recurrence of pain and subsequent 
elevation of PTP has been shown. (Ebbehøj N Scand J Gastroenterol. 1990). On the other 
hand, ductal dilatation has been observed in the absence of ductal obstruction giving rise to 
the suggestion that dilatation may also be related to parenchymal destruction; this is 
supported by the association between duct dilatation and pancreatic insufficiency (Jensen 
AR Scand J Gastroent 1984). Thus, while PDSO is likely an important factor in generating 
pain, there are likely factors other than main pancreatic duct abnormalities that can also be 
implicated (Bornman PC W J Surg 2003). Furthermore, the role of side duct obstruction in 
the genesis of pain has not yet been clearly defined; it may be that side branch disease 
contributes to the development of an inflammatory mass in the pancreatic head which is 
recognised as important in driving the disease process (the so called “pacemaker” of 
disease) (Beger HG World J Surg 1990). 
2.2 Interaction between the processes of inflammation and damaged neural 
structures 
Histological studies have shown that there is invasion of neural tissue by inflammatory cells 
associated with chronic pancreatitis. This is accompanied by disruptions in the perineural 
sheaths which expose the internal neural compartments to the inflammatory response 
(Bockman DE Gastroenterol 1988). In addition, there are increased amounts of pain 
transmitted substances, pain modulators and nerve growth factors and receptors in enlarged 
/ damaged pancreatic nerve structures, which appear to correlate with the intensity and 
frequency of pain (Büchler M Pancreas 1992, Zhu ZW Dig Dis Sci 2001,McMahon SP Nat 
Med 1995,Friess H Ann Surg 1999). Surgical resection of a pancreatic inflammatory mass 
effectively removes the pain stimulus together with the altered / damaged neural 
structures.  
2.3 Toxin metabolism and generation of excessive oxygen derived free radicals 
resulting in electrophilic stress and inflammation 
Acinar cells and proliferated islets of Langerhans are known to express cytochrome P450 
(CYP) mono-oxygenases which metabolise xenobiotics (substances foreign to a living 
organism), often utilizing glutathione & catalysed by glutathione transferases. (Foster JR J 
Pathol 1993). There may however be adverse consequences to these metabolic reactions with 
the generation of reactive oxygen species (ROS) and toxic xenobiotic metabolites. Prevention 
of cellular injury relies on defences against ROS and xenobiotic metabolites; these defences 
include: selenium dependant glutathione peroxidase, glutathione transferases, glutathione 
and ascorbic acid. These varied properties make the pancreas a versatile yet vulnerable 
xenobiotic metabolizing organ (Braganza JM JOP 2010; Foster JR. Toxicology of the exocrine 
pancreas. In: General and applied toxicology 2009). Inhaled xenobiotics (such as cigarette 
smoke, occupational volatile hydrocarbons and petrochemicals) that pass through the 
pulmonary circulation represent the biggest threat by striking the pancreas through its rich 
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arterial supply (Braganza JM Lancet 2011). When the acinar cell’s defence mechanisms are 
insufficient to meet the increased oxidant load from ROS and xenobiotic metabolites, 
eletrophilic stress results (Braganza JM Digestion 1998; Braganza JM JOP 2010; Foster JR. 
Toxicology of the exocrine pancreas. In: General and applied toxicology 2009). Dietary 
insufficiency of micronutrients and ascorbic acid may predispose to this (Braganza JM 
Digestion 1998). Electrophilic stress in turn results in pancreastasis, the failure of apical 
exocytosis in the acinar cell (Sanfey H Ann Surg 1984; Leung P Antioxid Redox Signal 2009). 
Enzymes (both newly synthesised & those stored in zymogen granules) not able to be 
released apically, are released via the basolateral memebrane into the interstitium, 
lymphatics and bloodstream (Cook LJ Scand J Gastroenterol 1996). Entrance of enzymes and 
free radical oxidation products into the interstitium causes mast cell degranulation, resulting 
in local inflammation, activation of nociceptive axon reflexes and fibrosis. (Cook LJ Scand J 
Gastroenterol 1996; Braganza JM Digestion 1998). This inflammatory response is potentiated 
by cytokines produced by the damaged acinar cell as a result of activated signaling cascades 
caused by the release of ROS. (Leung P Antioxid Redox Signal 2009).  
2.4 Fibrosis as a result of pancreatic stellate cell activation in the necrosis-
inflammation-fibrosis sequence and sentinel acute pancreatitis events 
Pancreatic stellate cells play a central role in the fibrotic process associated with chronic 
pancreatitis (Stevens T Am J Gastroenterol 2004). This is particularly relevant in the necrosis-
inflammation-fibrosis sequence, the most widely accepted hypothesis in the pathogenesis of 
chronic pancreatitis (Bornman PC in Chronic pancreatitis. Hepatobiliary and pancreatic 
surgery – a companion to specialist surgical practice. 2009). Initially this hypothesis held that 
fibrosis developed as a stepwise progressive process from recurrent bouts of acute 
pancreatitis (Comfort MW Gastroenterology 1946; Kloppel G Hepatogastroenterol 1991). An 
alternative theory suggested that alcohol might be directly toxic to the acinar cell through a 
change in cellular metabolism (toxic-metabolic theory). Alcohol was purported to produce 
cytoplasmic lipid accumulation within the acinar cell, leading to fatty degeneration, cellular 
necrosis and eventual fibrosis (Bordalo O Am J Gastroenterol 1977). More recently the theory 
of a sentinel acute pancreatitis event (SAPE) has been proposed. This theory hypothesizes 
that stimulation of the pancreatic acinar cell by alcohol or oxidative stress activates trypsin 
which results in a sentinel acute pancreatitis event. This is followed by a dual phase chronic 
inflammatory response, with the early phase characterised by a pro-inflammatory cell 
infiltrate including macrophages and lymphocytes. Cytokines released during the early 
phase also attract a later anti-inflammatory cellular infiltrate comprising pro-fibrotic cells, 
including stellate cells. These cells, once attracted, are activated by lipid peroxidation 
products (caused by excess ROS) and mast cell degranulation products, and are considered 
“primed”; continued stimulation by cytokines (in particular TGF-β1) produced by acinar 
cells, inflammatory cells or the stellate cells themselves as a result of oxidative stress, alcohol 
or recurrent acute pancreatitis, cause these activated stellate cells to deposit collagen, 
resulting in fibrosis and the features of chronic pancreatitis (Whitcomb DC Best Pract Res 
Clin Gastroenterol 2002). The transient formation of fatty acid ethanol esters and the role of 
macrophages and lymphocytes in pancreatic tissue destruction are also thought to be integral 
to this process (Pandol SJ Pancreatology 2007). It is suggested that the contractive potential 
and perivascular location of the stellate cells results in fibrosis that leads to microvascular 
ischaemia and pain (Wells RG Gastroenterol 1998). 
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2.5 Primary duct hypothesis 
This theory suggests a primary immunological attack on ductal epithelium leading to 
inflammation and scarring of ductal architecture. This may have specific relevance in 
autoimmune pancreatitis. (Cavallini G. Ital J Gastroenterol 1993). 
Once inflammation becomes established in CP, patients may enter a phase of stable 
disease with the histological features of acinar loss, mononuclear cell infiltrate and 
fibrosis (Shrikhande SV Br J Surg 2003). Subsequent progression to end stage disease is 
characterised by loss of all secretory tissue, disappearance of inflammatory cells and 
intense fibrosis. This may be accompanied by loss of pancreatic function together with 
diminished pain, the so-called “pancreatic burn-out syndrome”; this phenomenon is 
however not a universal outcome in patients with CP, thereby confounding potential 
treatment strategies (Girdwood AH J Clin Gastroenterol 1981; Amman RW Gastroenterol 
1984; Lankisch PG Digestion 1993). 
Complications of CP related to inflammation and fibrosis may develop which can alter the 
course of disease as well as clinical presentation. These include 
1. Biliary obstruction  
This is common in advanced disease, particularly when there calcification and an 
inflammatory mass in the head. Obstruction may be transient when related to oedema 
during acute flaring of disease or more permanent when occurring as a result of a fibrotic 
stricture or mass effect from an adjacent pseudocyst. .  
2. Duodenal obstruction 
This may be the result of peri-duodenal fibrosis or from the mass effect provided by a 
pseudocyst. 
3. Development of a pseudocyst / pancreatic ascites 
Pancreas related fluid collections or pseudocysts occur in 30-40% of patients with CP and 
are thought to be the consequence of either ductal obstruction or pancreatic necrosis with 
ductal disruption (D’Egidio A BJS 1991). Typically cysts communicate with the pancreatic 
ductal system which shows gross morphological abnormalities. Postnecrotic peripancreatic 
collections occur only rarely, usually as a consequence of an acute on chronic attack of 
pancreatitis. Pseudocysts in CP are usually located either near the head when they are 
mostly intra-pancreatic or in the lesser sac. Pseudocysts in CP are less likely to 
spontaneously resolve than those associated with acute disease as they have usually 
matured by the time of presentation and typically communicate with the pancreatic ductal 
system. Pancreatic ascites occurs when there is rupture of a pseudocyst or duct into the 
peritoneal cavity (Bornman PC in Hepatobiliary and pancreatic surgery – a companion to 
specialist surgical practice. 2009). 
4. Gastro-intestinal bleeding, related to 
a. Portal hypertension 
Portal hypertension may develop in up to 10% of patients as a result of venous compression 
or thrombosis. Splenic vein thrombosis may result in segmental portal hypertension giving 
rise to gastric and oesophageal varices, although frank variceal bleeding in this setting is 
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uncommon (Bornman PC in Hepatobiliary and pancreatic surgery – a companion to 
specialist surgical practice. 2009). 
b. Pseudoaneurysms 
Enzyme rich fluid collections may erode into vascular structures resulting in false 
aneurysms with bleeding into the cyst and pancreatic duct, peritoneum or retroperitoneum. 
3. Rationale and indications for surgical intervention 
Surgery is indicated in chronic pancreatitis for the relief of pain, to manage complications 
and to resect confirmed or suspected neoplastic disease (Bornman PC S Afr Med J 2010). 
Two theoretical principles underlie the rationale for surgery to alleviate pain in CP. The first 
utilises the ductal / parenchymal tissue hypertension and inflammatory-neural theories on 
the pathogenesis of pain in CP. It postulates that surgical decompression of the main 
pancreatic duct will alleviate interstitial hypertension thereby improving parenchymal 
perfusion and acidosis (Patel AG Gastroent 1995) with consequent reduction of 
inflammatory stimulation and influx of mediators into damaged nerves (Salim AS HPB Surg 
1997). The second principle focuses on removal of pathologically inflamed parenchyma 
together with altered neural tissue in particular that within the head, which is considered 
the “pacemaker” of disease. Emphasis has also been placed on the importance of addressing 
diseased side ducts, thereby limiting the possibility of recurrence (Beger HG World J Surg 
1990). 
The objectives of surgery for pain in CP are effective and durable relief of symptoms while 
preserving endocrine and exocrine function, thereby restoring the patient’s quality of life. 
The potential for morbidity and mortality as well as recurrence should be low. Based on 
these objectives and the principles outlined above, a number of procedures have been 
developed. Essentially, these procedures fall into a spectrum covering three broad 
categories. At one end of the spectrum are drainage procedures which focus on 
decompressing the main pancreatic duct by establishing a new pancreatic-enteric 
communication which bypasses any native obstruction to pancreatic outflow. At the other 
end of the spectrum are resectional procedures which aim to remove diseased ductal and 
neural tissue within chronically inflamed parenchyma. Over time, a number of modified 
and hybrid procedures have evolved which attempt to retain the advantages while limiting 
the disadvantages of both the former 2 categories. 
Little data exists to guide decision making regarding the optimal timing of surgery to 
alleviate pain in CP. There are two schools of thought. The first suggests that conservative 
non-surgical management should be pursued for as long as possible in order to avoid 
morbidity and side effects that may be associated with surgical intervention, in particular 
pancreatic insufficiency. They argue that the long term outcome of surgery is no different 
from medical management, and that the “pancreatic burn-out syndrome” is likely 
responsible for pain relief observed after surgery (Amman RW gastroenterol 1984). In 
contrast to this, others have argued that pain relief is better when surgical drainage is 
carried out earlier rather than later (Nealon WH Ann Surg 1993). It also remains 
controversial whether surgery can delay the natural course of the disease in terms of 
deterioration in pancreatic function (Warshaw AL Gastroenterol 1980; Nealon WH Ann 
Surg 1993; Jalleh RP Ann Surg 1992). Both arguments appear to have merit. While it seems 
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foolhardy to offer surgical intervention with it’s attached risk of morbidity and even 
mortality in patients whose symptoms might be controlled by medical means, it seems 
equally unreasonable to persist with a conservative approach in anticipation of pain relief, 
delaying surgery until narcotic addiction has developed and the outcomes from surgery 
may be worse (Warshaw AL gastroenterol 1984). In the absence of good evidence to guide 
decision making, it seems most appropriate that the decision regarding timing of surgery be 
individualized on a patient to patient basis. Surgical intervention should be performed only 
once an adequate trial of medical therapy has failed to control symptoms and the patient has 
been counseled regarding the risks and benefits of both modalities.  
Patients referred for surgery for relief of intractable symptoms of CP should be evaluated by 
experienced clinicians working in a high volume, multi-disciplinary environment. All other 
treatment options should have been exhausted or considered not appropriate. Cross 
sectional imaging should be conducted to clearly delineate pancreatic morphology and 
detect local complications or features suggestive of neoplastic disease. The presence of 
portal hypertension, particularly as a result of portal or superior mesenteric vein thrombosis 
should be noted, as this may preclude surgical intervention (Bornman PC S Afr Med J 2010). 
With careful patient selection and modern surgical strategies, surgery may offer effective 
pain relief in over 90% of patients at 5 year follow up (Beger HG Ann Surg 1989).  
In considering intervention for complications of CP, the clinical picture is paramount in 
decision making. Biliary obstruction may be asymptomatic, detected only biochemically or 
during imaging for other indications. In addition, there may be transient jaundice as a result 
of oedema during acute flares of the disease. The above are not indications for intervention. 
It must be remembered that once the biliary system has been entered, either percutaneously, 
endoscopically or surgically, this once sterile system should be considered contaminated 
with the risk of sepsis developing should obstruction recur in the future. On the other hand, 
persistent biliary obstruction of sufficient duration may result in secondary biliary cirrhosis, 
atrophy and deterioration in hepatic function. (Abdallah A HPB 2007). Obstruction longer 
than 4 weeks should arouse concern and warrants intervention. Decompression by means of 
endoscopic stenting should only be considered as a temporary bridge to surgery, in acute 
cholangitis or where patient factors preclude surgery (Bornman PC S Afr Med J 2010). 
Duodenal obstruction on the other hand typically represents either advanced fibrosis or a 
clinically significant pseudocyst, neither of which are likely to resolve before progression or 
further complications develop. Intervention is therefore indicated. Pseudocysts in CP are 
less likely to resolve than their acute counterparts and thus more often require drainage. The 
indications for drainage are the presence of symptoms or complications. Although size 
alone is not a criterion for intervention, cysts larger than 6cm are more likely to be 
symptomatic and require treatment (Bornman PC S Afr Med J 2010). Percutaneous 
procedures are generally not favoured for these lesions due to an increased risk of failure, 
introducing sepsis or creating an external fistula. Endoscopic drainage is associated with a 
success rate of 65-95% and a low complication rate and is preferred to surgery due to its less 
invasive nature. (Beckingham IJ Br J Surg 1997). Strict morphological criteria are required 
however, relating to cyst maturity, intra-luminal bulging, wall thickness (less than 10mm) 
and vascularity, particularly in the presence of portal hypertension. To this end, careful 
cross sectional imaging and endoscopic ultrasound are important adjuncts in assessing 
patients for this modality of treatment. Transmural drainage may be transduodenal or 
transgastric depending on the best route into the cyst while transpapillary drainage is an 
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alternative option when communication with the pancreatic duct can be demonstrated. 
Surgery is indicated when endoscopic intervention fails or is not appropriate due to cyst 
morphology or patient factors. Surgical drainage of a pseudocyst may also be employed as 
part of an intervention planned for treatment of pain or additional complications. Pancreatic 
ascites is an uncommon but serious complication of CP which is managed in the first 
instance with paracentesis, nutritional support and endoscopic stenting of the pancreatic 
duct (Kozarek RA Gastrointest Endosc Clin North Am 1998; Bornman PC in Hepatobiliary 
and pancreatic surgery – a companion to specialist surgical practice 2009). Use of a 
somatostatin analogue remains controversial. Surgery is reserved for failures of conservative 
treatment. Bleeding from gastric varices related to segmental portal vein thrombosis is 
uncommon, thus the authors recommend intervention only once there is proven bleeding 
from gastric varices. Haemorrhage related to a pseudoaneurysm is best dealt with via 
selective angiography and embolisation due to the hazards of surgery in this setting. 
Surgery is reserved for failure of angiographic treatment. 
4. Surgery for chronic pancreatitis – Drainage procedures 
For many years longitudinal pancreaticojejunostomy (LPJ) as described by Partington and 
Rochelle in 1960 was the favoured surgical option in the treatment of chronic pancreatitis. 
This involves entering and laying open of the pancreatic duct followed by a splenic 
preserving pancreaticojejunostomy without resection of the pancreatic tail (Partington PF, 
Rochelle REL. Ann Surg 1960). This procedure is relatively simple in comparison to many of 
the other available operations and has a low mortality and morbidity with maximal 
pancreatic tissue preserved. Pain relief in the short term approximates 75% but there is 
frequently recurrence in the long term (Bachmann K Best Pract and res Clin Gastro 2010). 
This is thought to be due to incomplete decompression of the main pancreatic duct, 
particularly in the head. There remains a residual inflammatory mass containing altered 
nerve fibres (Pessaux P Pancreas 2006) as well as obstructed second and third order ducts 
causing ongoing intraductal hypertension (Markowitz JS Arch Surg 1994). Current 
indications for this procedure are isolated dilatation of the pancreatic duct greater than 7mm 
or where the duct has a “chain of lakes” appearance without an inflammatory mass in the 
head (Yekebas EF Ann Surg 2006). Where the duct is undilated (less than 3mm) a 
longitudinal V-shaped excision of the ventral pancreas combined with a longitudinal 
pancreatico-jejunostomy has been described (Izbicki JR Ann Surg 1998, 227). This may be 
particularly useful when a sclerosing form of chronic pancreatitis results in so called small 
duct disease (Bachmann K Best Pract and res Clin Gastro 2010). Good results with pain relief 
in 89% of patients and comparable morbidity of 19.6% have been reported (Yekebas EF Ann 
Surg 2006).  
5. Surgery for chronic pancreatitis – Resectional procedures 
With recognition that inflamed, fibrotic tissue containing damaged neural structures within 
the pancreatic head is critical in the generation of symptoms, pancreaticoduodenectomy 
became the gold standard in surgical treatment against which other procedures were 
measured. It has been assumed that outcomes concerning pain and quality of life are better 
than simple drainage procedures performed in isolation, however clear evidence of this is in 
randomized trials is lacking.  
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In the modern era, pylorus preservation as in a Pylorus Preserving Pancreaticoduodenectomy 
(PPPD) has been shown to result in less pain and nausea and improved quality of life when 
compared with the traditional Whipples pancreaticoduodenectomy (Mobius C Langenbecks 
Arch Surg 2007). This procedure can be performed with a mortality of 5-10% and morbidity of 
20-40% and improves pain and quality of life in both the short and long term in up to 90% of 
patients (Bachmann K Best Pract and res Clin Gastro 2010). There are however a number of 
disadvantages relating to the sacrifice of functional pancreatic parenchyma and the non-
diseased duodenum and common bile duct. The loss of natural bowel continuity and reduced 
endocrine and exocrine function result in side effects and reduced quality of life (Izbicki JR 
Ann Surg 1998 (228); Koninger J Surgery 2008). In order to allow organ preservation and 
reduce adverse effects, duodenum preserving resections of the pancreatic head (DPPHR) were 
developed. The Beger procedure was introduced in 1980 and was the first to include these 
principles (Beger HG Chirurg 1980). It consists of a subtotal resection of the head following 
transection of the pancreas above the portal vein. The Pancreas is then drained by an end-to-
side or end-to-end pancreaticojejunostomy using a Roux-en-Y loop. Physiological 
gastroduodenal passage and CBD continuity are therefore preserved. This procedure could be 
performed with low mortality (0-3%) and morbidity (15-32%) and long term pain relief in 75-
95% of patients (Izbicki JR Ann Surg 1995, Buechler MW J Gastrointest Surg 1997Frey CF Ann 
Surg 1994). The Frey procedure (Frey CF Pancreas 1987) subsequently combined an LPJ (as 
described by Partington and Rochelle) with a limited duodenum preserving excision of the 
head. Following exploration of the main pancreatic duct well into both the head and the tail, 
the head is cored out leaving a small cuff of parenchyma along the duodenal wall. This results 
in a lesser resection of the head than that described by Beger. In further contrast to the Beger 
operation, the pancreas is not divided over the SMV/portal vein complex making it an easier 
operation to perform. Care is taken not to enter the CBD. Drainage of the resection cavity 
within the head and from the opened main pancreatic duct within the body and tail is 
obtained with an LPJ using a Roux-en-Y loop (Frey CF Pancreas 1987). Good results have been 
obtained with substantial pain relief in more than 85% of patients while mortality is less than 
1% and morbidity 9-39% (Izbicki JR Ann Surg 1995, Izbicki JR Ann Surg 1998, Beger HG Ann 
Surg 1989). Endocrine & exocrine function are well preserved and the operation may control 
complications such as CBD stenosis, duodenal stenosis and internal pancreatic fistulas. The 
Frey operation is currently the most widely performed operation for patients with an 
inflammatory mass in the head together with pancreatic duct dilatation while the Beger 
procedure is reserved for patients where the main pancreatic duct is not dilated (Bornman PC 
S Afr Med J 2010). 
Two further modifications of the above procedures have been described. The Hamburg 
operation employs subtotal excision of the pancreatic head including the uncinate process( a 
more extensive resection than the Frey operation but comparable to Beger’s procedure) 
together with a V-shaped excision of the ventral aspect of pancreas into the pancreatic duct. 
Pancreatic-enteric continuity is re-established with an LPJ using a Roux-en-Y loop 
(comparable to the Partington-Rochelle and Frey reconstructions).This operation combines 
aspects of the Frey and Beger procedures, without transection of gland over SMV/portal 
vein. The extent of resection is customized to pancreatic morphology while the V-shaped 
excicion creates a trough-like new ductal system allowing better drainage of ductal side 
branches (Izbicki JR Ann Surg 1998, 227, Bachmann K Med Sci Monit 2008). In the Berne 
operation, an extensive duodenum-preserving resection of the head is performed (as in the 
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Beger procedure), but without division of pancreas anterior to superior mesenteric / portal 
vein complex and without laying open the pancreatic duct in the body and tail. In biliary 
obstruction a longitudinal opening may be made in the CBD within the cavity created in the 
pancreatic head. Drainage of the cavity is achieved with a pancreatic-enteric anastamosis to 
small bowel in a Roux-en-Y reconstruction similar to the reconstructions described above. 
Results of the Berne procedure are comparable to the other duodenum preserving resections 
(Gloor B Dig Surg 2001). 
Little comparative data is available to guide choice between the various available 
procedures in CP. Four randomized controlled trials have been conducted comparing PPPD 
with DPPHR, with 2 providing long term follow up (table 1). In the short to medium term,  
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QOL= quality of life; pre-op= pre-operative; post-op= post-operative; FU= follow up; PPPD= pylorus 
preserving pancreatico-duodenectomy; NS= not significant; IDDM= insulin dependant diabetes mellitus; 
DM= diabetes mellitus: Prof rehab= professional rehabilitation; EORTC= European Organisation for 
Research and Treatment of Cancer; QLQ= Quality of Life Questionnaire; s.d= standard deviation 
Buchler MW Am J Surg 1995  
Klempa I Chirurg 1995 
Izbicki JR Ann Surg 1998; 228 
Farkas G Langenbecks Arch Surg 2006 
Muller MW Br J Surg 2008 
Strate T Gastroenterology 2008 
Table 1. Outcomes of Pylorus preserving pancreaticoduodenectomy (PPPD) vs duodenum 
preserving pancreatic head resection (DPPHR) 
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QOL= quality of life; pre-op= pre-operative; post-op= post-operative; GTT= glucose tolerance test; FU= 
follow up; NS= not significant; DM= diabetes mellitus: Prof rehab= professional rehabilitation; EORTC= 
European Organisation for Research and Treatment of Cancer; QLQ= Quality of Life Questionnaire  
Izbicki JR Ann Surg 1995 
Strate T Ann Surg 2005 
Koninger J Surgery 2008 
Table 2. Comparisons of duodenum preserving resections of the pancreatic head. 
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there was evidence for significant benefit of DPPHR over PPPD in terms of morbidity (2 
trials), pain relief (2 trials), quality of life (1 trial), endocrine function (1 trial ), exocrine 
function (1 trial) and weight gain (2 trials). In addition, 2 trials showed a benefit for DPPHR 
in terms of operating time while hospital stay and requirement for blood transfusion were 
improved in 1 trial each. A Cochrane review on short term outcomes concluded that there 
was benefit for DPPHR in respect of quality of life and professional rehabilitation, exocrine 
insufficiency, weight gain, hospital stay and intra-operative blood replacement. There was 
also a trend towards reduced post-operative diabetes (Diener MK Ann Surg 2008). 
However, in the 2 studies examining long term outcomes, it was seen that many of the short 
term clinical benefits described above were not maintained. Proposed reasons for this were 
study error related to the small population sizes studied and that pancreatic gland burn-out 
might be delayed by DPPHR (Muller MW Br J Surg 2008). Nevertheless, at 14 year follow up 
there remained a trend towards better endocrine function, while there was significant 
benefit in terms of appetite, subjective feeling of well being and mean period of employment 
after surgery for patients undergoing DPPHR(Muller MW Br J Surg 2008). Thus, while short 
term results favour DPPHR over PPPD in CP, long term results appear equivalent and 
probably reflect the natural course of the disease. 
Only 2 randomized trials have compared different DPPHR procedures, with 1 trial 
undergoing long term follow up (table 2). The first trial compared the Beger and Frey 
procedures with no significant differences being found in the short term apart from a benefit 
for the Frey operation in terms of morbidity. After a median of 8.5 years, all variables had 
comparable outcomes while almost all patients were noted to be exocrine insufficient 
(Izbicki JR Ann Surg 1995; Strate T Ann Surg 2005). The second study compared the Beger 
and Berne procedures, suggesting a benefit for the Berne operation in terms of operation 
time and hospital stay. Results were analysed on intention to treat basis however, including 
8 out of 32 (Beger procedure) and 6 out of 33 (Berne procedure) patients who had their 
operations altered for technical reasons. When patients were analysed per protocol ie only 
those who underwent their assigned procedure, only the difference in operating times 
remained significant. 
More extensive pancreatic resections such as total or near total distal pancreatectomy offer 
only short term relief and are associated with significant mortality and morbidity, often as a 
result of markedly reduced pancreatic function. They have largely been abandoned with 
their main role being as salvage procedures for complications relating to previous surgical 
interventions (including anastamotic leakage, pancreatic fistula and intractable pain 
following previous adequate resection or drainage surgery). 
6. Surgery for the complications of chronic pancreatitis 
Surgery for the complications of CP should be individualized to cater to a patient’s specific 
morphology and clinical presentation. 
6.1 Biliary obstruction 
Choledocho-duodenostomy or hepatico-jejunostomy using a Roux-en-Y loop are the 
preferred procedures to resolve isolated biliary obstruction although the former may result 
in enteric refux and a sump-like syndrome. Cholecysto-enterostomy has been associated 
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with poor results and has fallen into disfavour. A Hepatico-jejunostomy may be included in 
the Roux loop used to drain the pancreatic duct in dedicated drainage, resection or hybrid 
procedures performed to relieve pain. Alternatively, the CBD may opened within the 
surgically created cavity in the pancreatic head during the Berne procedure. 
6.2 Duodenal obstruction 
Surgical relief of obstruction related to a fibrotic stricture involves duodenal mobilization by 
Kocher’s maneouvre with division of all fibrotic tissue. Should this be insufficient to restore 
patency, duodeno-duodenostomy or a gastro-jejunostomy may be considered, although the 
latter may be associated with biliary reflux. Where biliary obstruction co-exists in the 
presence of duodenal obstruction together with an inflammatory mass in the head, two 
options exist: PPPD or gastric bypass with a gastro-jejunostomy as part of the Roux drainage 
limb in a DPPHR. 
6.3 Development of a pseudocyst 
The choice of surgical procedure is dictated by the location of the pseudocyst and its 
proximity to a section of bowel suitable for drainage. Cyst-gastrostomy, cyst-duodenostomy 
and cyst-jejunostomy may all be employed depending on individual patient characteristics. 
Distal pancreatectomy may be employed for segmental disease within the body/tail 
together with an associated pseudocyst (Bornman PC S Afr Med J 2010). Surgery for 
pancreatic fistulae / ascites entails either a roux-en-Y jejunostomy to the fistula tract or an 
appropriate resection. 
6.4 Gastro-intestinal bleeding, related to 
a. Portal hypertension 
Patients who have bled from gastric varices related to segmental portal hypertension as a 
consequence of splenic vein thrombosis can usually be managed with distal 
pancreatectomy.  
b. Pseudoaneurysms 
Where angiographic embolisation has failed to control a bleeding pseudoaneurysm vascular 
control may be achieved using a Frey-type procedure in preference to a more extensive 
resection which may be hazardous under these circumstances, while bleeding from the tail 
can usually be dealt with safely by means of a distal pancreatectomy (Bornman PC S Afr 
Med J 2010). 
Surgery for suspected malignancy should utilize either a pancreatico-duodenectomy or 
distal pancreatectomy depending on tumour location and should be performed in keeping 
with the oncological principle of clear resection margins. 
7. Conclusion 
The pathophysiology of chronic pancreatitis is complex and as yet incompletely understood, 
confounding attempts at effective management strategies. The clinical picture is dominated 
by progressive pain which may become intractable and pancreatic endocrine and exocrine 
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dysfunction which may severely impact on a patient’s quality of life. Surgery aims to relieve 
ductal and tissue hypertension related to obstruction in the main and side branch ducts 
while also removing inflamed and fibrotic parenchymal tissue containing diseased nerve 
fibres. Duodenal preserving pancreatic head resections, usually combined with drainage of 
the main pancreatic duct, achieve both objectives with short and long term relief of pain in 
approximately 90% of patients at 5 year follow up. By preserving some parenchymal tissue 
these procedures attempt to limit pancreatic functional insufficiency. With acceptable 
morbidity and mortality figures, they have evolved as the surgical procedure of choice for 
the majority of patients with pain refractory to medical treatment. Surgery for complications 
of CP should be individualized while resection for neoplastic disease should be performed 
according to oncological principles, ensuring a clear margin of resection. More extensive 
resections should generally only be performed as salvage procedures for complications of 
previous surgery. Patients requiring surgery for chronic pancreatitis should be evaluated 
and treated by experienced surgeons in high volume centres utilizing a multi-disciplinary 
approach. Prior to undergoing surgery for pain, patients should have completed an 
adequate trial of medical therapy and been thoroughly counseled regarding the risks of 
surgery and its likely outcomes. 
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